Becton, Dickinson and Company
As of Fiscal Year 2025 (ended September 30, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $21.84 billion, up 8.2% year-over-year as reported (7.7% adjusted for currency, 2.9% organic) |
| Net income, GAAP (FY2025) | $1.678 billion, down 1.6% year-over-year |
| Diluted EPS, GAAP (FY2025) | $5.82, down 0.7% year-over-year |
| Adjusted diluted EPS, non-GAAP (FY2025) | $14.40, up 9.6% year-over-year |
| Gross profit / gross margin (FY2025) | $9.93 billion gross profit, 45.4% of revenue (up from 45.2% in FY2024) |
| Operating income / operating margin, GAAP (FY2025) | $2.579 billion, 11.8% of revenue, up 7.6% year-over-year |
| Adjusted operating margin, non-GAAP (FY2025) | 25.0% of revenue, up about 80 basis points year-over-year |
| R&D spending (FY2025) | $1.265 billion, up 6.3% year-over-year (about 5.8% of revenue) |
| Employees (as of September 30, 2025) | Approximately 72,000 associates across 61 countries |
| Pending portfolio change | Biosciences & Diagnostic Solutions business (within BD Life Sciences) is pending combination with Waters Corporation, expected to close around end of Q1 calendar 2026; not yet reflected as a separation in FY2025 results |
Sources: All figures are GAAP as reported by Becton, Dickinson and Company (BD) in its Q4/full-year FY2025 earnings release (Form 8-K furnished November 6, 2025, for the period ended September 30, 2025) and its FY2025 Form 10-K (filed November 2025), unless otherwise noted. BD's three reportable segments in FY2025 were BD Medical, BD Life Sciences, and BD Interventional; BD did not disclose operating income by segment in these filings, so only segment revenue is shown. BD's Biosciences & Diagnostic Solutions business (part of BD Life Sciences) is pending combination with Waters Corporation, expected to close around the end of the first calendar quarter of 2026; it remained part of BD's continuing operations throughout FY2025, so FY2025 figures reflect BD as structured prior to that separation. Effective October 1, 2025 (the start of FY2026), BD reorganized into five new segments (Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences); that new structure does not apply to the FY2025 results shown here. No credible, specifically-sourced third-party market-share estimate for a BD product category could be confirmed with reasonable search effort, so that widget was omitted rather than fabricated.